All Trials

Randomized Phase 2 Trial of Maintenance Oral Etoposide or Observation Following High-dose Chemotherapy for Relapsed Metastatic Germ-Cell Tumor

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with relapsed non-seminomatous germ-cell tumor (including ovarian GCT) who completed two tandem cycles of high-dose chemotherapy with peripheral-blood stem-cell transplant and have nonrising AFP/hCG are randomized to maintenance oral etoposide 50 mg daily versus observation. Etoposide is a cytotoxic topoisomerase II inhibitor used here as low-dose maintenance to reduce micrometastatic relapse risk.

ClinicalTrials.gov ID: NCT04804007

A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study of oral belzutifan, a selective HIF-2α inhibitor, for adults with recurrent or persistent clear cell ovarian carcinoma (≥50% clear cell if mixed) with measurable disease after at least one prior platinum regimen; prior bevacizumab and immunotherapy allowed and treated/stable brain metastases permitted. Patients receive daily belzutifan in 28-day cycles until progression/toxicity, with primary endpoints of ORR and 6-month PFS; class-toxicities include anemia and hypoxia.

ClinicalTrials.gov ID: NCT06677190

A Phase 2, Open-label, Single-arm Study Of Autologous Memory Cytokine Enriched Natural Killer (M-CENK) Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent, platinum‑resistant high‑grade epithelial ovarian, primary peritoneal, or fallopian tube cancer (ECOG 0–1; prior bevacizumab required and PARP inhibitor if BRCA+) receive gemcitabine plus autologous memory‑like NK cell therapy (M‑CENK) with N‑803, an IL‑15 superagonist that expands NK and CD8 T cells. The regimen starts with gemcitabine, then adds repeated M‑CENK infusions and subcutaneous N‑803 from cycle 2 until cell product exhaustion or progression.

ClinicalTrials.gov ID: NCT06710288

A Phase 1/2, Open-label, Dose-escalation Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Combination With Pembrolizumab (Phase 1 and Phase 2) and Pembrolizumab and Pegylated Liposomal Doxorubicin (Phase 1b) in Patients With Platinum Resistant or Refractory Ovarian Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with platinum-resistant or -refractory recurrent ovarian, fallopian tube, or primary peritoneal cancer with a lesion amenable to intratumoral/intraperitoneal injection receive the oncolytic adenovirus TILT-123 (igrelimogene litadenorepvec; tumor-selective adenovirus expressing TNFα and IL-2 to inflame TME and recruit/activate T cells) plus pembrolizumab, with a cohort also adding pegylated liposomal doxorubicin. Suitable for ECOG 0–1 patients without active autoimmune disease; Phase 1/1b defines dose and evaluates the triplet, and Phase 2 expands TILT-123 + pembrolizumab.

ClinicalTrials.gov ID: NCT05271318

Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with newly diagnosed FIGO III–IV high-grade serous ovarian, fallopian tube, or primary peritoneal carcinoma planned for neoadjuvant chemotherapy are randomized to standard carboplatin/paclitaxel plus bevacizumab with surgery and maintenance versus the same regimen plus intraperitoneal IMNN-001 (GEN-1), a DNA–lipopolymer IL‑12 immunotherapy that enhances local T/NK-cell activity, given weekly through adjuvant therapy and continued with bevacizumab in HRP/BRCA– patients. Trial assesses histologic minimal residual disease at second-look laparoscopy, with PFS and OS as secondary endpoints.

ClinicalTrials.gov ID: NCT05739981

A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Recurrent high‑grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer after 1–2 prior lines, measurable disease, enrolling to receive the oral WEE1 kinase inhibitor azenosertib (ZN‑c3) combined with standard relapse regimens (carboplatin, PLD, paclitaxel, gemcitabine) or bevacizumab. WEE1 inhibition abrogates G2/M and intra‑S checkpoints to force mitotic catastrophe; study is multi‑arm dose‑escalation/expansion to define safe doses and assess preliminary activity.

ClinicalTrials.gov ID: NCT04516447

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with newly diagnosed FIGO stage III–IV high‑grade serous/endometrioid ovarian, fallopian tube, or primary peritoneal cancer with pathogenic BRCA1/2 mutation or HRD+ status after response to first‑line platinum are randomized to maintenance olaparib for 1 year vs 2 years, with optional bevacizumab. Olaparib is an oral PARP1/2 inhibitor exploiting HRD via synthetic lethality; bevacizumab is an anti‑VEGF monoclonal antibody given at physician discretion for up to 1 year.

ClinicalTrials.gov ID: NCT06580314

Combination Therapy With Liposomal Doxorubicin and Withaferin A (Ashwagandha, ASWD) in Recurrent Ovarian Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant or refractory recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma eligible for single-agent liposomal doxorubicin receive DOXIL 40 mg/m2 q4wk plus daily oral Ashwagandha (withaferin A–rich extract) at the phase I–selected dose. Withaferin A is a multi-target botanical agent (NF-κB inhibition, ER stress induction, cytoskeletal disruption) combined with standard DOXIL to assess safety and early efficacy; excludes prior anthracyclines/liposomal doxorubicin and significant cardiac disease (LVEF ≥55% required).

ClinicalTrials.gov ID: NCT05610735

A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with newly diagnosed FIGO III–IV high-grade epithelial ovarian/fallopian tube/primary peritoneal carcinoma whose tumors express HER2 (IHC 3+/2+/1+) and who completed frontline platinum plus bevacizumab are randomized to maintenance trastuzumab deruxtecan (HER2-targeted antibody–drug conjugate delivering a topoisomerase I inhibitor) plus bevacizumab versus bevacizumab alone. Excludes patients with BRCA mutations or on PARP maintenance and those with significant bleeding risk or prior/current ILD/pneumonitis.

ClinicalTrials.gov ID: NCT06819007

Phase 1/2a Open-Label, Dose-Escalation, Multicenter, FIH, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to TNFR 2 As a Single Agent and in Combination with Pembrolizumab (MK-3475-D20) in Subjects with Advanced Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced solid tumors or T‑cell lymphomas (including CTCL) after failure/intolerance of standard therapy, ECOG 0–1, measurable disease, and biopsy‑amenable tumors receive BI‑1808, a human IgG1 anti‑TNFR2 antibody that blocks TNF‑α/TNFR2 signaling and may deplete TNFR2+ Tregs, given IV every 3 weeks as monotherapy or combined with pembrolizumab. Excludes active CNS metastases, significant autoimmune disease, recent anticancer therapy, or active infections; expansion cohorts include ovarian cancer, melanoma, and T‑cell lymphomas.

ClinicalTrials.gov ID: NCT04752826